Genentech, MedImmune end patent rift over Synagis

06/11/2008 | Bloomberg Businessweek · TheStreet.com

Genentech and MedImmune have reached an agreement to resolve a patent dispute over motavizumab and Synagis, a respiratory drug. The settlement allows MedImmune -- a unit of AstraZeneca PLC -- to receive licenses for selected pipeline products under a patent Genentech co-owns with City of Hope National Medical Center.

View Full Article in:

Bloomberg Businessweek · TheStreet.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC